<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844762</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-19145</org_study_id>
    <secondary_id>1R21DA046333-01A1</secondary_id>
    <nct_id>NCT04844762</nct_id>
  </id_info>
  <brief_title>Addiction and Behavior Related to Menthol Cigarette Substitutes</brief_title>
  <acronym>MENTHOL</acronym>
  <official_title>Addiction and Behavior Related to Menthol Cigarette Substitutes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed study is to examine the abuse liability and substitutability of&#xD;
      plausible menthol cigarette alternatives currently on the market, including menthol filtered&#xD;
      little cigars (mFLC), menthol roll-your-own (mRYO) pipe tobacco and cigarette tubes, and&#xD;
      non-menthol cigarettes (nmC). In addition, the study will elucidate real-time mechanisms&#xD;
      including product characteristics and perceived effects associated with greater substitution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using an in-laboratory and ad libitum outpatient mixed design, 80 current menthol cigarette&#xD;
      smokers will complete a three phase, 3 week study: in Phase 1, utilizing a randomized&#xD;
      crossover design, participants will complete 5 smoking sessions, each session smoking a&#xD;
      different product examining each participants puff topography while sampling the product, the&#xD;
      products' ability to suppress nicotine craving/withdrawal, and the product's demand indices.&#xD;
      Products will include participants usual brand menthol cigarette (UBMC) as well as 3&#xD;
      commercially-available alternatives, including an mFLC, a pre-assembled mRYO product (menthol&#xD;
      tobacco and non-menthol tube), and an nmC. All sessions will occur following 12 hours of&#xD;
      nicotine abstinence and be separated by 48 hours. In Phase 2, participants will select their&#xD;
      preferred study product from Phase 1 and be instructed to completely substitute the product&#xD;
      for their UBMC for one week. Participants will complete ecological momentary assessments&#xD;
      (EMA) during this period to more accurately assess degree of substitution and perceived&#xD;
      effects in real time. In Phase 3, participants will complete a final in-lab visit to assess&#xD;
      the substitutability of their preferred product, under simulated ban conditions using a&#xD;
      progressive ratio task. In all phases, multiple domains of abuse liability will be assessed,&#xD;
      including product administration (in-lab puff topography and EMA self-report measures),&#xD;
      product liking and craving and withdrawal suppression (in-lab and EMA self-report), and a&#xD;
      hypothetical purchase task to simulate demand.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 16, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Puff duration</measure>
    <time_frame>Phase 1 - Up to 2 weeks</time_frame>
    <description>The duration of each puff, in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inter-puff-interval</measure>
    <time_frame>Phase 1 - Up to 2 weeks</time_frame>
    <description>The time between each puff, in seconds.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Puff flow rate</measure>
    <time_frame>Phase 1 - Up to 2 weeks</time_frame>
    <description>The rate of air flow during each puff, n ml/second.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total puff volume</measure>
    <time_frame>Phase 1 - Up to 2 weeks</time_frame>
    <description>The volume of each puff, in ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Effects/Liking Questionnaire</measure>
    <time_frame>Phases 1-3 - Up to 3 weeks</time_frame>
    <description>An adapted version of the Drug Effects/Liking Questionnaire will assess the desire and liking of UBMC and all three study products, positive and negative effects (i.e., side effects), and perceived strength and effectiveness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Cigarette Evaluation Questionnaire (mCEQ)</measure>
    <time_frame>Phase 1 - Up to 2 weeks</time_frame>
    <description>The modified Cigarette Evaluation Questionnaire (mCEQ) will assess subjective responses to cigarettes (e.g., reward, satisfaction).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Cigarette Evaluation Questionnaire (mCEQ)</measure>
    <time_frame>Phase 3 - Approximately 3 hours</time_frame>
    <description>The modified Cigarette Evaluation Questionnaire (mCEQ) will assess subjective responses to cigarettes (e.g., reward, satisfaction).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cigarette Purchase Task</measure>
    <time_frame>Phase 1 - Up to 2 weeks</time_frame>
    <description>The Cigarette Purchase Task will ask participants how much they would be willing to pay (ranging from 0 cents to $1) to smoke each product. Given that the study products will look similar to cigarettes, we will retain the original language (e.g., 1 cigarette) in the purchase task. Willingness to spend more will indicate greater abuse liability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cigarette Purchase Task</measure>
    <time_frame>Phase 3 - Approximately 3 hours</time_frame>
    <description>The Cigarette Purchase Task will ask participants how much they would be willing to pay (ranging from 0 cents to $1) to smoke each product. Given that the study products will look similar to cigarettes, we will retain the original language (e.g., 1 cigarette) in the purchase task. Willingness to spend more will indicate greater abuse liability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form (modified)</measure>
    <time_frame>Phase 1-3 - Up to 3 weeks</time_frame>
    <description>Smoking urges/craving will be measured using the Tiffany-Drobes Questionnaire of Smoking Urges: Brief Form. This is a 10-item measure where participants rate smoking-related items (All I want right now is a cigarette) on a 7-point Likert scale ranging from strongly agree to strongly disagree. Similar to previous studies, we will collapse the items into two previously identified factors (Factor 1: strong desire and intention to smoke; Factor 2: anticipation of relief from withdrawal symptoms).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minnesota Nicotine Withdrawal Scale</measure>
    <time_frame>Phase 1-3 - Up to 3 weeks</time_frame>
    <description>Nicotine withdrawal will be assessed using the empirically validated 15-item version of the Minnesota Nicotine Withdrawal Scale. This measure assesses smoking craving, anger/irritability, anxiety, depressed mood, restlessness/difficulty concentrating, increased appetite, sleep problems, and somatic symptoms (nausea, constipation, sore throat, dizziness, coughing).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjective effects (EMA)</measure>
    <time_frame>Phase 2 - 1 week</time_frame>
    <description>Subjective effects (EMA) of the Phase 2 substitute product will be derived from daily diary EMAs assessing product satisfaction and pleasure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross Price Elasticity Task</measure>
    <time_frame>Phases 1 - Up to 2 weeks</time_frame>
    <description>A Cross-Price Task in Phases 1 and 3 will estimate substitutability of the study product for the UBMC. Participants will be asked how many study products and UBMCs they would consume when the price of the study product is fixed at $1 and the UBMC prices escalate. The data are then fit to an exponential equation that indicates whether the fixed-price product substitutes for the primary product, and the degree of substitution. Cross price elasticity (CPE) for each study product compared to UBMC &gt; 0.2 indicates substitution, CPE &lt; -0.2 indicates complementarity, and CPE between -0.2 and 0.2 indicate independence of the two products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cross Price Elasticity Task</measure>
    <time_frame>Phase 3 - Approximately 3 hours</time_frame>
    <description>A Cross-Price Task in Phases 1 and 3 will estimate substitutability of the study product for the UBMC. Participants will be asked how many study products and UBMCs they would consume when the price of the study product is fixed at $1 and the UBMC prices escalate. The data are then fit to an exponential equation that indicates whether the fixed-price product substitutes for the primary product, and the degree of substitution. Cross price elasticity (CPE) for each study product compared to UBMC &gt; 0.2 indicates substitution, CPE &lt; -0.2 indicates complementarity, and CPE between -0.2 and 0.2 indicate independence of the two products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive ratio task (UBMC vs. study product)</measure>
    <time_frame>Phase 3 - Approximately 3 hours</time_frame>
    <description>The PR task will simulate the effect that restricting menthol in cigarettes would have on increasing (or not) preference for other alternative menthol substitutes. Participants will complete a 90-minute concurrent choice task with different cost (effort) required to earn the reinforcement (2 puffs) from their UBMC and the study product (mFLC or mRYO). Puffs from the study product can be earned by clicking a computer mouse 10 times on a picture of the study product, but to earn two puffs of the UBMC, they will required to make escalating response requirements (computer mouse clicks) according to the following schedule: 10, 160, 320, 640, 1280, 2400, 3600, 4800, 6000, 7200, and 8400. A maximum of 10 reinforcers (20 puffs) per session will be allowed. Participants will be informed of the different sequence between products and instructed that the session are 3 hours in length no matter how much or how little they respond.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Use behavior (EMA)</measure>
    <time_frame>Phase 2 - 1 week</time_frame>
    <description>Participants will receive on EMA delivered randomly during the day and an evening daily diary (around 30mins before bedtime). Random EMAs will assess: mood, affect, nicotine craving and withdrawal symptoms, stress, recency of smoking, alcohol use, current setting, and switching self-efficacy; daily diary EMAs will assess UBMC/study product smoked per day, product satisfaction and pleasure. Substitution assessed via use behavior during Phase 2 will be operationalized as the ratio of study product to UBMC used, with a ratio &gt; 0 indicating any substitution and a ratio &gt; 1 indicating substitution of study product for the UBMC at least 50% of the time.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Smoking (Tobacco) Addiction</condition>
  <arm_group>
    <arm_group_label>usual brand menthol cigarette (UBMC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participant's usual brand menthol cigarette</description>
  </arm_group>
  <arm_group>
    <arm_group_label>menthol roll-your-own cigarette (mRYO)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mentholated pipe tobacco in a roll-your-own cigarette tube</description>
  </arm_group>
  <arm_group>
    <arm_group_label>menthol filtered little cigar (mFLC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The menthol filtered cigar will be Cheyenne (Cheyennecigars.com) Seneca (senecacigars.com)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-menthol cigarette (nmC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The non-menthol cigarette will be Newport non-menthol cigarettes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Menthol cigarettes substitutes</intervention_name>
    <description>In Phase 1, participants will complete 4 smoking sessions using a different product each session to examine each product's abuse liability.</description>
    <arm_group_label>menthol filtered little cigar (mFLC)</arm_group_label>
    <arm_group_label>menthol roll-your-own cigarette (mRYO)</arm_group_label>
    <arm_group_label>non-menthol cigarette (nmC)</arm_group_label>
    <arm_group_label>usual brand menthol cigarette (UBMC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual brand menthol cigarettes and substitutes</intervention_name>
    <description>In Phase 2, to assess uptake, changes in subjective effects, and use over time, participants will select their preferred study product from Phase 1 and be instructed to completely substitute the product for their usual brand menthol cigarette for one week.</description>
    <arm_group_label>menthol filtered little cigar (mFLC)</arm_group_label>
    <arm_group_label>menthol roll-your-own cigarette (mRYO)</arm_group_label>
    <arm_group_label>non-menthol cigarette (nmC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Menthol cigarettes substitutes and menthol cigarettes</intervention_name>
    <description>In Phase 3, participants will complete a final in-lab visit to assess the substitutability of their preferred product from Phases 1 and 2, under simulated ban conditions using a progressive ratio task.</description>
    <arm_group_label>menthol filtered little cigar (mFLC)</arm_group_label>
    <arm_group_label>menthol roll-your-own cigarette (mRYO)</arm_group_label>
    <arm_group_label>non-menthol cigarette (nmC)</arm_group_label>
    <arm_group_label>usual brand menthol cigarette (UBMC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  current menthol cigarette smoker (&gt;90% menthol cigarette use; â‰¥5 cigarettes per day)&#xD;
             for at least the past 6 months.&#xD;
&#xD;
          -  between 18-24 (young adult) or 25-50 years old (aged 25+)&#xD;
&#xD;
          -  willing to provide informed consent and abstain from all tobacco and nicotine use for&#xD;
             at least 12 hours prior to the five lab sessions&#xD;
&#xD;
          -  willing to complete one week of EMA&#xD;
&#xD;
          -  read and speak English.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  self-reported diagnosis of lung disease including asthma, cystic fibrosis, or chronic&#xD;
             obstructive pulmonary disease&#xD;
&#xD;
          -  unstable or significant psychiatric conditions (past and stable conditions will be&#xD;
             allowed)&#xD;
&#xD;
          -  history of cardiac event or distress within the past 3 months&#xD;
&#xD;
          -  currently pregnant, planning to become pregnant, or breastfeeding (will be verified&#xD;
             with urine pregnancy test)&#xD;
&#xD;
          -  use of other tobacco products (e.g., e-cig, cigar, etc.) &gt;5 days in the past month&#xD;
&#xD;
          -  current marijuana use &gt;5 times per month&#xD;
&#xD;
          -  any use of other illicit drugs during the last 30 days (verified by urinalysis at&#xD;
             initial visit)&#xD;
&#xD;
          -  currently engaging in a smoking cessation attempt&#xD;
&#xD;
          -  currently using one of the alternative menthol study products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodore Wagener, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohio State Comprehensive Cancer Center</last_name>
    <phone>800-293-5066</phone>
    <email>OSUCCCClinicaltrials@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Wagener, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>Jamesline</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 2, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Theodore Wagener</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Menthol cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

